rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ZYME
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Zymeworks at Jefferies Global Healthcare Conference: pipeline breadth and capital discipline
      Nov 17Investing.comZYMEJEF
      Zymeworks Chief Scientific Officer Andrew Paul Moore Sells $1M After Modest Run-Up
      Nov 16BenzingaZYME
      Zymeworks authorizes $200 million share buyback program through 2028
      Nov 16Investing.comZYME
      Citizens raises Zymeworks stock price target on pipeline progress
      Nov 13Investing.comZYME
      Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
      Nov 12Yahoo FinanceZYME
      Zymeworks at stifel 2026 healthcare conference: royalties, deals and growth
      Nov 11Investing.comZYMESF
      Zymeworks earnings missed by $0.08, revenue topped estimates
      Nov 10Investing.comZYME
      Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
      Nov 9Yahoo FinanceZYME
      Zymeworks faces earnings test on strategic transformation
      Nov 9Investing.comZYME
      Zymeworks stock hits 52-week high at 31.43 USD
      Nov 4Investing.comZYME
      Zymeworks (ZYME) Stock May Be Overvalued On Its New Lung Cancer Deal

      Zymeworks has delivered a very strong share price run over the past few years, and the recent licensing deal activity has sharpened the question of what investors are really paying for today. With the stock now reflecting both past gains and fresh expectations, the core issue is how that market value lines up against the company’s book value. Over the past 3 years, Zymeworks has produced a share price gain of roughly 3x. This puts a lot of history and optimism on the line when you compare...

      Nov 4Yahoo FinanceZYME
      Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

      Zymeworks (ZYME) has drawn fresh attention after two October announcements: new Phase 1 data for its antibody drug conjugate ZW191 in ovarian cancer, and a wide-ranging licensing deal with Roche for trispecific candidate ZW209. Those catalysts have arrived after a period of strong momentum, with Zymeworks’ share price delivering a 19.8% 1 month return and 28.2% 3 month return, while total shareholder return over the past year is 65.9% and roughly 4x over three years. Scan other high-momentum...

      Nov 4Yahoo FinanceZYME
      Zymeworks (ZYME) Receives a Buy from Truist Financial

      Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.

      Oct 31The Globe and MailZYME
      Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates - Slideshow
      Oct 29Seeking AlphaZYME
      Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

      Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 29Yahoo FinanceZYME
      Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
      Oct 27Yahoo FinanceZYME
      Truist raises Zymeworks stock price target on pipeline progress
      Oct 27Investing.comZYME
      How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing Deal
      Oct 26Yahoo FinanceZYME
      Zymeworks stock price target reaffirmed at $32 by Citizens
      Oct 26Investing.comZYME
      Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancer

      Phase 1 Zymeworks ovarian cancer data show strong anti-tumor activity for ZW191 in heavily pretreated patients. Read more here.

      Oct 24Seeking AlphaZYME
      Zymeworks reports trial results for ovarian cancer drug ZW191
      Oct 24Investing.comZYME
      Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
      Oct 24Yahoo FinanceZYME
      Jefferies raises Zymeworks stock price target on Roche deal
      Oct 23Investing.comZYME
      Why is Zymeworks stock surging today?
      Oct 23Investing.comZYME
      Zymeworks stock surges on $813M Roche licensing deal
      Oct 23Investing.comZYME
      Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones
      Oct 23Yahoo FinanceZYME
      Zymeworks licenses cancer drug candidate ZW209 to Roche for $55m
      Oct 23Investing.comZYME
      Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
      Oct 23ReutersZYME
      Zymeworks appoints Suzanne Monahan as commercial head
      Oct 19Investing.comZYME
      Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

      Detailed price information for Zymeworks Inc (ZYME-Q) from The Globe and Mail including charting and trades.

      Oct 19The Globe and MailZYME
      Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
      Oct 15Yahoo FinanceZYME
      Zymeworks EVP Schayowitz sells $357,557 in shares
      Oct 12Investing.comZYME
      Zymeworks EVP Adam Schayowitz sells $357,557 in shares
      Oct 11Investing.comZYME
      Zymeworks EVP Adam Schayowitz sells $357,557 in ZYME stock for taxes
      Oct 10Investing.comZYME
      Zymeworks EVP, head of R&D Adam Schayowitz sells $357,557 in stock.
      Oct 9Investing.comZYME
      Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire
      Oct 9Yahoo FinanceZYME
      Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
      Oct 2Yahoo FinanceTBPHZYME
      Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition
      Sep 29Investing.comZYME
      Zymeworks stock rating maintained at outperform by Citizens
      Sep 29Investing.comZYME
      Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Zymeworks (NASDAQ

      Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.

      Sep 28BenzingaTBPHZYME
      Zymeworks Inc. (ZYME) Theravance Biopharma, Inc. - M&A Call - Slideshow (NASDAQ:ZYME) 2026-09-28
      Sep 28Seeking AlphaTBPHZYME
      Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance

      Zymeworks (ZYME) said Monday it has completed its acquisition of Theravance Biopharma, adding Yupelr

      Sep 28Yahoo FinanceTBPHZYME
      Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
      Sep 28Yahoo FinanceTBPHZYME
      Zymeworks Completes Acquisition of Theravance Biopharma

      Zymeworks (ZYME) said late Wednesday it completed its previously announced $929 million acquisition

      Sep 23Yahoo FinanceZYME
      Theravance Biopharma shareholders approve merger with Zymeworks
      Sep 18Investing.comTBPHZYME
      Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME)

      Zymeworks Inc. remains a Buy, leveraging validated technology, strong price momentum, and upcoming catalysts. Read more on ZYME stock here.

      Sep 18Seeking AlphaTBPHZYME
      Zymeworks at Morgan Stanley conference: approval, cash and pipeline
      Sep 14Investing.comZYMEMS
      Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

      Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailAXSMOCGNZYME
      Zymeworks at Wells Fargo conference: cash flow, zanidatamab drive
      Sep 8Investing.comZYMEWFC
      Zymeworks stock hits 52-week high at 30.75 USD
      Sep 2Investing.comZYME

      This is the newest page. Registered accounts read further back.